More than 100 Democratic members of Congress urged the Trump administration to remove pending language from the U.S.-Mexico-Canada Agreement trade agreement that would lock the U.S into at least 10 years of marketing exclusivity for biologics, a move they argue will hurt taxpayers and patients.
In a letter sent on Thursday to U.S. Trade Representative Robert Lighthizer, the lawmakers cited a provision of the deal, which has not yet been ratified, that would prevent a company seeking to sell a lower-cost version of a brand-name biologic from doing so for a decade. For this reason, they maintain the trade pact as it currently stands runs counter to efforts by President Trump to lower drug prices.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
